Related Experiment Video
Updated: Dec 13, 2025
Candida albicans Biofilm Development on Medically-relevant Foreign Bodies in a Mouse Subcutaneous Model Followed by Bioluminescence Imaging
Published on: January 27, 2015
Intermittent micafungin for prophylaxis in a rat model of chronic Candida albicans gut colonization
Peter Warn1, Pia Thommes1, Andrew Sharp1
1Evotec (UK) Ltd, Block 23 Alderley Park, Macclesfield, Cheshire SK10 4TG, UK.
Background:
During antifungal prophylaxis, micafungin is generally infused IV once daily over 1 h. In practice, less-frequent dosing could improve the quality of life in patients requiring long-term treatment or prophylaxis. The feasibility of this approach was assessed using humanized doses of daily or infrequent micafungin regimens.
Objectives:
To evaluate the effectiveness of intermittent high-dose micafungin, simulating human exposure, for prophylaxis of invasive candidiasis in a rat model of chronic Candida albicans gastrointestinal colonization and systemic dissemination.
Methods:
Two weeks post-infection with an oral challenge of C. albicans, Sprague-Dawley rats were immunocompromised with a cytotoxic drug and a steroid. Rats received IV infusions of: daily vehicle control; daily subcutaneous micafungin (20 mg/kg SC); high-dose micafungin (20 mg/kg bolus SC + 80 mg/kg infusion/72 h, to simulate intermittent human dosing of 300 mg/72 h); or daily fluconazole by mouth (10 mg/kg PO). The effects of antifungal prophylaxis on faecal fungal burden and systemic C. albicans dissemination were evaluated.
Results:
A rat model of chronic C. albicans gastrointestinal colonization and systemic dissemination was established, characterized by a sustained microbiological burden over 29 days and fungal recovery from normally sterile tissues. Using this model, intermittent high-dose micafungin (delivered via iPrecio pumps) to simulate humanized doses of 300 mg/72 h was significantly more effective than vehicle control, as effective as once-daily micafungin and similar to daily fluconazole at reducing faecal burden and preventing systemic dissemination.
Conclusions:
These data indicate that intermittent high-dose micafungin can be as effective as daily therapy, supporting clinical assessment in high-risk patients requiring long-term antifungal prophylaxis.
Insights
Intermittent high-dose micafungin (an antifungal) proved as effective as daily dosing for preventing invasive candidiasis in a rat model. This finding supports exploring less frequent micafungin administration for long-term patient prophylaxis.
Area of Science:
- Mycology
- Pharmacology
- Infectious Diseases
Background:
- Micafungin is typically administered intravenously once daily for antifungal prophylaxis.
- Less frequent dosing could enhance patient quality of life during long-term treatment.
- The study investigated the feasibility of intermittent micafungin regimens.
Purpose of the Study:
- To evaluate the efficacy of intermittent high-dose micafungin in preventing invasive candidiasis.
- To simulate human exposure to micafungin in a rat model.
- To assess prophylaxis in a model of chronic Candida albicans gastrointestinal colonization and systemic dissemination.
Main Methods:
- A rat model was established with chronic Candida albicans gastrointestinal colonization and systemic dissemination.
- Rats were immunocompromised and received daily vehicle control, daily micafungin, intermittent high-dose micafungin (simulating 300 mg/72h), or daily fluconazole.
- Effects on fecal fungal burden and systemic dissemination were evaluated.
Main Results:
- The established rat model showed sustained microbiological burden and fungal recovery from sterile tissues.
- Intermittent high-dose micafungin significantly reduced fecal burden and prevented systemic dissemination compared to controls.
- Intermittent micafungin was as effective as daily micafungin and similar to daily fluconazole.
Conclusions:
- Intermittent high-dose micafungin demonstrated comparable efficacy to daily therapy in the studied rat model.
- These findings suggest that intermittent micafungin could be a viable option for long-term antifungal prophylaxis in high-risk patients.
- Further clinical assessment of intermittent micafungin dosing is warranted.
